J. Walz to Prostate-Specific Antigen
This is a "connection" page, showing publications J. Walz has written about Prostate-Specific Antigen.
Connection Strength
0.678
-
Bjerner J, Bratt O, Aas K, Albertsen PC, Foss? SD, Kv?le R, Lilja H, M?ller C, M?ller S, Stensvold A, Thomas O, R?e OD, Vickers A, Walz J, Carlsson SV, Oldenburg J. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium. Eur Urol. 2024 Jul; 86(1):20-26.
Score: 0.203
-
Walz J, Chun FK, Klein EA, Reuther A, Graefen M, Huland H, Karakiewicz PI. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy. Eur Urol. 2009 Feb; 55(2):412-19.
Score: 0.074
-
Walz J, Suardi N, Hutterer GC, Perrotte P, Gallina A, B?nard F, Valiquette L, McCormack M, Graefen M, Montorsi F, Karakiewicz PI. Lower urinary tract symptoms affect one-third of men in a prostate cancer screening population. J Endourol. 2008 Feb; 22(2):369-76.
Score: 0.070
-
Ahyai SA, Graefen M, Steuber T, Haese A, Schlomm T, Walz J, K?llermann J, Briganti A, Zacharias M, Friedrich MG, Karakiewicz PI, Montorsi F, Huland H, Chun FK. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter. Eur Urol. 2008 Apr; 53(4):750-7.
Score: 0.069
-
Gallina A, Jeldres C, Chun FK, Shariat SF, Briganti A, Walz J, Roehrborn CG, Saad F, Huland H, Graefen M, Montorsi F, Karakiewicz PI. Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. Eur Urol. 2007 Nov; 52(5):1374-80.
Score: 0.065
-
Deivasigamani S, Kotamarti S, Rastinehad AR, Salas RS, de la Rosette JJMCH, Lepor H, Pinto P, Ahmed HU, Gill I, Klotz L, Taneja SS, Emberton M, Lawrentschuk N, Wysock J, Feller JF, Crouzet S, Kumar M P, Seguier D, Adams ES, Michael Z, Abreu A, Jack Tay K, Ward JF, Shinohara K, Katz AE, Villers A, Chin JL, Stricker PD, Baco E, Macek P, Ahmad AE, Chiu PKF, Crawford ED, Rogers CG, Futterer JJ, Rais-Bahrami S, Robertson CN, Hadaschik B, Marra G, Valerio M, Chong KT, Kasivisvanathan V, Tan WP, Lomas D, Walz J, Guimaraes GC, Mertziotis NI, Becher E, Finelli A, Kasraeian A, Lebastchi AH, Vora A, Rosen MA, Bakir B, Arcot R, Yee S, Netsch C, Meng X, de Reijke TM, Tan YG, Regusci S, Benjamin TGR, Olivares R, Noureldin M, Bianco FJ, Sivaraman A, Kim FJ, Given RW, Dason S, Sheetz TJ, Shoji S, Schulman A, Royce P, Shah TT, Scionti S, Salomon G, Laguna P, Tourinho-Barbosa R, Aminsharifi A, Cathelineau X, Gontero P, Stabile A, Grummet J, Ledbetter L, Graton M, Stephen Jones J, Polascik TJ. Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement. Eur Urol. 2023 12; 84(6):547-560.
Score: 0.051
-
Fanti S, Briganti A, Emmett L, Fizazi K, Gillessen S, Goffin K, Hadaschik BA, Herrmann K, Kunikowska J, Maurer T, MacLennan S, Mottet N, Murphy DG, Oprea-Lager DE, O'Sullivan JM, Oyen WJG, Rouvi?re O, Sartor O, Stenzl A, Van Poppel H, Walz J, Witjes W, Bjartell A. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. Eur Urol Oncol. 2022 10; 5(5):530-536.
Score: 0.048
-
Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, Barbato F, Weber M, Ilhan H, Cervati V, Wetter A, Hadaschik B, Briganti A, Walz J, Pianori D, Fanti S, Haberkorn U, Herrmann K, Fendler WP. 68Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study. J Urol. 2019 12; 202(6):1174-1181.
Score: 0.039
-
Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Albersen M, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Van Der Poel H, Walz J, De Meerleer G, Bossi A, Haustermans K, Van Poppel H, Spahn M, Joniau S. The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. Eur Urol Focus. 2018 04; 4(3):369-375.
Score: 0.033
-
Joniau S, Spahn M, Briganti A, Gandaglia G, Tombal B, Tosco L, Marchioro G, Hsu CY, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes RJ, Montorsi F, van Poppel H, Gontero P. Pretreatment tables predicting pathologic stage of locally advanced prostate cancer. Eur Urol. 2015 Feb; 67(2):319-25.
Score: 0.027